Description:
This is a randomized, double-blinded study designed to evaluate the efficacy, safety,
pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A)
or placebo in combination with platinum-based chemotherapy in participants with resectable
Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label
adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Title
- Brief Title: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
- Official Title: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Clinical Trial IDs
- ORG STUDY ID:
GO40241
- NCT ID:
NCT03456063
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Tecentriq | Arm A: Atezolizumab + platinum-based chemotherapy |
Placebo Comparator | | Arm B: Placebo + platinum-based chemotherapy |
Nab-paclitaxel | Abraxane | Arm A: Atezolizumab + platinum-based chemotherapy |
Pemetrexed | Alimta | Arm A: Atezolizumab + platinum-based chemotherapy |
Carboplatin | | Arm A: Atezolizumab + platinum-based chemotherapy |
Cisplatin | | Arm A: Atezolizumab + platinum-based chemotherapy |
Gemcitabine | Gemzar | Arm A: Atezolizumab + platinum-based chemotherapy |
Purpose
This is a randomized, double-blinded study designed to evaluate the efficacy, safety,
pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A)
or placebo in combination with platinum-based chemotherapy in participants with resectable
Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label
adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm A: Atezolizumab + platinum-based chemotherapy | Experimental | Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy
Platinum-based chemotherapy may include:
carboplatin + pemetrexed
carboplatin + nab-paclitaxel
cisplatin + pemetrexed
cisplatin + gemcitabine
Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab | - Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Nab-paclitaxel
- Pemetrexed
- Carboplatin
- Cisplatin
- Gemcitabine
|
Arm B: Placebo + platinum-based chemotherapy | Placebo Comparator | Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy
Platinum-based chemotherapy may include:
carboplatin + pemetrexed
carboplatin + nab-paclitaxel
cisplatin + pemetrexed
cisplatin + gemcitabine
Participants will receive best supportive care and monitoring after surgery | - Placebo Comparator
- Nab-paclitaxel
- Pemetrexed
- Carboplatin
- Cisplatin
- Gemcitabine
|
Eligibility Criteria
Inclusion criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB
(T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on
the 8th edition of the AJCC/UICC staging system
- Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection
with curative intent
- Adequate pulmonary and cardiac function to undergo surgical resection
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end organ function
- Negative HIV test at screening
- Negative for active HBV and HCV at screening
- Adequate tissue for PD-L1 IHC assessment
Exclusion criteria:
- NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
- Mixed NSCLC and small cell lung cancer histology
- Any prior therapy for lung cancer
- Malignancies other than NSCLC within 5 years prior to randomization, with the
exception of those with a negligible risk of metastasis or death treated expected
curative outcome
- Non-squamous NSCLC histology with activating ALK and EGFR mutation
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, or evidence of active of active pneumonitis on screening chest Computed
Tomography (CT) scan
- Prior treatment with cluster of differentiation 137 (CD137) agonist or immune
checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1
therapeutic antibody
- Severe infection within 4 weeks prior to randomization
- Significant history of cardiovascular disease
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first. |
Secondary Outcome Measures
Measure: | Pathological Complete Response (pCR) |
Time Frame: | At time of surgery |
Safety Issue: | |
Description: | pCR is defined as the absence of any viable primary tumor cells at the time of surgical resection in the primary tumor as assessed by central and local pathology laboratory. |
Measure: | Major Pathological Response (MPR) |
Time Frame: | At time of surgery |
Safety Issue: | |
Description: | MPR is defined as ≤ 10% residual viable tumor cells at the time of surgical resection in the primary tumor, as assessed by central and local pathology laboratory. |
Measure: | Overall Survival (OS) |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | OS is defined as the time from randomization to death from any cause during the course of the study. |
Measure: | Investigator-Assessed EFS |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the investigator; or death from any cause, whichever occurs first. |
Measure: | Disease-Free Survival (DFS) |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | DFS is defined as the time from the first date of no disease to local or distant recurrence (including occurrence of new primary NSCLC) or death due to any cause, whichever occurs first, as determined by the investigator during the adjuvant treatment and observation follow-up |
Measure: | Objective Response (OR) |
Time Frame: | Prior to surgery, up to approximately 84 days |
Safety Issue: | |
Description: | Objective response is defined as a complete response or partial response, as determined by the investigator according to RECIST v1.1 |
Measure: | 2-Year and 3-Year OS |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | The 2-year and 3-year OS rate is defined as the probability that a participant will be alive 2 years and 3 years after randomization, respectively. |
Measure: | 2-Year and 3-Year Independent Review Facility-Assessed EFS |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Independent Review Facility. |
Measure: | 2-Year and 3-Year Investigator-Assessed EFS |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Investigator. |
Measure: | Change from baseline in HRQoL scores |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | Change from baseline in HRQoL scores as assessed through use of the two-item GHS/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30 at each assessment time point during the study through the completion of adjuvant treatment and observation follow-up assessments |
Measure: | Percentage of Participants With Adverse Events (AEs) |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | |
Measure: | Number and Severity of Surgical Related Adverse Events |
Time Frame: | Up to approximately 81 months |
Safety Issue: | |
Description: | |
Measure: | Minimum Observed Serum Atezolizumab Concentration (Cmin) |
Time Frame: | Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 81 months) |
Safety Issue: | |
Description: | Cmin is the minimum (or trough) concentration that a study drug achieves in the body. |
Measure: | Maximum Observed Serum Atezolizumab Concentration (Cmax) |
Time Frame: | Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 81 months) |
Safety Issue: | |
Description: | Cmax is the maximum (or peak) concentration that a study drug achieves in the body. |
Measure: | Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab |
Time Frame: | Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 81 months) |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Hoffmann-La Roche |
Last Updated
August 5, 2021